Abstract
Background Post-COVID-19 condition (PCC) affects millions globally, presenting as persistent multisystem symptoms. Despite various hypotheses, the biological mechanisms underlying PCC remain unclear. Previous studies have linked PCC to alterations in the DNA methylome of blood immune cells, but the effects on lung cells over time remain unknown.
Methods Patients (n=13) with persistent symptoms following COVID-19 in 2020-2021 donated blood and sputum samples at inclusion and after one year. Symptom and physiological testing data were collected concurrently. DNA methylation (DNAm) profiles were analysed longitudinally and compared to pre-pandemic DNAm data from healthy controls.
Results While peripheral blood mononuclear cells (PBMCs) showed no significant changes, longitudinal DNAm changes were observed in neutrophil- and macrophage-enriched fractions. The changes were significantly associated with symptoms and physiological measures. Pathway analysis showed enrichment for cellular processes involved in cardiac function.
Conclusions We identified longitudinal DNAm changes in lung immune cells associated with pathways linked to cardiac function. These changes correlate with symptom burden and heart and lung metrics. The results suggest potential disease mechanisms and aid the development of diagnostic tools.
Competing Interest Statement
ML, MG, SS and DM are founders of a company, which has the ambition to develop DNAm-based biomarkers for a variety of conditions, including PCC. The other authors declare no competing interests.
Funding Statement
This work was supported by the Swedish Heart Lung foundation, as a sub-project within the project: Deciphering infection related epigenetic dynamics to explain the variability of human susceptibility to COVID-19 and tuberculosis (Grant no. 2022-0034). Funding was also granted from local grant (Student to Docent) and regional ALF-grant in Region Ostergotland, Sweden. The enabling of data handling was partially funded by the Swedish Research Council (Grant no. 2018-05973).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of Swedish Ethical Review Authority (Dnr. 2021‐01620) gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data sharing and availability
The deidentified processed data that support the findings of this study are available from the corresponding author upon reasonable request.
